Compounds > hydroxyurea
Page last updated: 2024-10-28

hydroxyurea and Apoplexy

hydroxyurea has been researched along with Apoplexy in 134 studies

Research Excerpts

ExcerptRelevanceReference
"We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria."9.69Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023)
" SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania."9.69Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023)
" In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)."9.51Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022)
"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)."9.15Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011)
"In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial."9.12Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007)
"Our findings suggest that hydroxyurea is safe and may prevent silent stroke and stroke in sickle cell disease."9.01The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019)
"We demonstrated changes in SCD care utilization over time, including increased hydroxyurea use, changes in transfusion rates, and increased attention to iron overload management."8.31Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023)
"We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death."7.81Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015)
" Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities."7.80Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014)
" In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect."7.80Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014)
"To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)."7.79Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013)
" We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA."7.77Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011)
"For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload."7.72Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004)
" A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke."7.71Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002)
"Hydroxyurea is an alternative treatment to decrease stroke risk."7.30Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023)
" The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates."6.78Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013)
"Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated."6.77Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012)
"Ischemic stroke is characterized by high morbidity, disability, and mortality."5.91Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023)
" SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania."5.69Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023)
"We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria."5.69Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023)
" We performed a secondary analysis of participants in the Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria trial, a double-blind, parallel-group randomized controlled trial for low-dose or moderate-dose hydroxyurea in children with abnormal transcranial Doppler velocities and a comparison group of participants with nonelevated transcranial Doppler velocities in northern Nigeria."5.69Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting. ( Abdullahi, SU; Acra, S; DeBaun, MR; Gambo, S; Klein, LJ; Rodeghier, M; Stallings, VA, 2023)
" In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)."5.51Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022)
"Evidence-based practice for stroke prevention in high-income countries involves screening for abnormal transcranial Doppler (TCD) velocity and initiating regular blood transfusions for at least 1 year, followed by treatment with hydroxyurea."5.51Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team. ( Bahago, GY; Bauman, AA; Bello-Manga, H; DeBaun, MR; Farouk, B; Haliru, L; King, AA; Sani, AM; Suleiman, A; Tabari, AM, 2022)
"Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD."5.51Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019)
"Hydroxyurea-induced pneumonitis is unusual."5.40[Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014)
"Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis."5.40Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014)
"The standard care protocol requires that children with acute strokes be treated with hydroxyurea at a fixed dose of 20 mg/kg/day within two months of the stroke."5.30Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial. ( Abdullahi, SU; DeBaun, MR; Galadanci, NA; Jordan, LC; Rodeghier, M, 2019)
"There is evidence to suggest that hydroxyurea may be effective in decreasing the frequency of pain episodes and other acute complications in adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life-threatening neurological events in those with sickle cell anaemia at risk of primary stroke by maintaining transcranial Doppler velocities."5.22Hydroxyurea (hydroxycarbamide) for sickle cell disease. ( Nevitt, SJ; Rankine-Mullings, AE, 2022)
"Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell anaemia (SCA) and abnormal TCD."5.22Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. ( Aygun, B; Cohen, AR; Davis, BR; Fuh, B; Imran, H; Luchtman-Jones, L; Pressel, SL; Schultz, WH; Thompson, AA; Ware, RE; Wood, JC, 2016)
" We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients."5.20Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015)
"The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial compared standard (transfusions/chelation) to alternative (hydroxyurea/phlebotomy) treatment to prevent recurrent stroke and manage iron overload in children chronically transfused over 7 years before enrollment."5.19Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. ( Adams, RJ; Aygun, B; Driscoll, C; Heeney, MM; Helton, KJ; Jackson, SM; Kesler, KL; Krishnamurti, L; Lockhart, A; Miller, ST; Sarnaik, SA; Schultz, WH; Ware, RE, 2014)
"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)."5.15Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011)
"In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial."5.12Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007)
" Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes."5.12Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence. ( Fields, ME; Hulbert, ML; Mayer, SL, 2021)
"Our findings suggest that hydroxyurea is safe and may prevent silent stroke and stroke in sickle cell disease."5.01The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019)
" The introduction of penicillin prophylaxis, conjugated pneumococcal and Haemophilus influenzae type B vaccines have dramatically decreased the rate of life-threatening infections, while use of hydroxyurea in children has decreased pain and acute chest syndrome events."4.90The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. ( DeBaun, MR; Kassim, AA, 2014)
" The first two trials addressed the use of chronic transfusion to prevent primary stroke; the third utilized the drug hydroxycarbamide (hydroxyurea) and phlebotomy to prevent both recurrent (secondary) stroke and iron overload in patients who had already experienced an initial stroke."4.89Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Dwan, K; Wang, WC, 2013)
" Improved understanding of the natural history of complications such as stroke and pulmonary hypertension, effects of treatments, such as hydroxyurea and blood transfusions, as well as the impact of transplantation on organ damage are likely to influence the timing and indication of transplantation."4.84Hematopoietic cell transplantation: a curative option for sickle cell disease. ( Krishnamurti, L, 2007)
" prevention of overwhelming bacterial infection, present indications and controversies regarding blood transfusion, prevention of stroke, acute chest syndrome, hydroxyurea therapy--probably the best disease modifying agent at the moment, stem cell transplantation--a cure and certain promising experimental therapies including gene therapy have been discussed in this review."4.82Advances in management of sickle cell disease. ( Agarwal, MB, 2003)
"We demonstrated changes in SCD care utilization over time, including increased hydroxyurea use, changes in transfusion rates, and increased attention to iron overload management."4.31Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023)
" These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin Sβ0 (HbSβ0) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbSβ0 thalassemia."3.96American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. ( Daraz, L; DeBaun, MR; Fox, CK; Jordan, LC; King, AA; Kirkham, FJ; Kraut, MA; McKinstry, RC; Murad, MH; Schatz, J; Telfer, P; Vichinsky, E, 2020)
"We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death."3.81Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015)
" Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities."3.80Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014)
" He was thought to have had an embolic stroke and was initially treated with warfarin."3.80Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014)
" In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect."3.80Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014)
"To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)."3.79Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013)
" We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA."3.77Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011)
"For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload."3.72Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004)
" A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke."3.71Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002)
" Optimal zinc dosing and the role of zinc in preventing stroke or death in SCA warrant further investigation."3.30Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. ( Bond, C; Conroy, AL; Cusick, SE; Datta, D; Goings, MJ; Jang, JH; John, CC; Krebs, NF; Namazzi, R; Opoka, R; Ryu, MS; Tagoola, A; Tu, W; Ware, RE, 2023)
"Hydroxyurea is an alternative treatment to decrease stroke risk."3.30Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023)
"Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox."3.01Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial. ( Cronin, RM; DeBaun, MR; Gay, JC; Hsu, P; Lin, CJ; Rodeghier, M, 2021)
" The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa."2.87Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018)
"The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking."2.84Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). ( Ali, S; Aliyu, MH; Amal Galadanci, A; Bello-Manga, H; Belonwu, R; Covert, BV; DeBaun, MR; Galadanci, NA; Jordan, LC; Kassim, AA; Kirkham, FJ; Musa Tabari, A; Neville, K; Phillips, S; Salihu, A; Shyr, Y; Umar Abdullahi, S; Vance, LD; Wudil Jibir, B, 2017)
"Stroke risk in sickle cell anemia (SCA), predicted by high transcranial Doppler (TCD) velocities, is prevented by transfusions."2.82Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. ( Arnaud, C; Bernaudin, F; Biscardi, S; Dalle, JH; Epaud, R; Fourmaux, C; Gluckman, E; Hau, I; Kamdem, A; Kasbi, F; Leveillé, E; Madhi, F; Pondarré, C; Socié, G; Vasile, M; Verlhac, S, 2016)
" The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates."2.78Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013)
"Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated."2.77Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012)
" Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality."2.75The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010)
"Hydroxyurea has hematologic and clinical efficacy in sickle cell anemia (SCA), but its effects on transcranial Doppler (TCD) flow velocities remain undefined."2.73Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. ( Burgett, S; Mortier, NA; Schultz, WH; Ware, RE; Zimmerman, SA, 2007)
"In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC)."2.71Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. ( Adams, R; Brambilla, D; Morales, KH; Olivieri, N; Scher, CD; Styles, L; Wang, WC, 2005)
"Stroke affects around 10% of children with sickle cell anaemia (HbSS)."2.66Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Hopewell, S; Kohli, R; Trivella, M; Wang, WC, 2020)
"Sickle cell disease is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes."2.55Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Fortin, PM; Hopewell, S; Trivella, M; Wang, WC, 2017)
"Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide."2.55Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017)
"Stroke is a significant cause of morbidity and mortality in children and adults with sickle cell disease."2.49Stroke in patients with sickle cell disease. ( Kwiatkowski, JL; Webb, J, 2013)
"Stroke is one of the most devastating complications of sickle cell disease, but current research has led to improved understanding of its pathogenesis and to new approaches in the prevention of both primary and secondary stroke."2.44The pathophysiology, prevention, and treatment of stroke in sickle cell disease. ( Wang, WC, 2007)
"Sickle cell disease is a recessively inherited condition in which synthesis of haemoglobin is abnormal."2.41Acute complications of sickle cell disease in children. ( , 2001)
"Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen."2.41[What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000)
"Youths with sickle cell anemia (SCA) are at risk of pain crises, stroke, and early death."1.91Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines. ( Anders, D; Cogan, LW; Dombkowski, KJ; Goel, A; Green, NS; Lisabeth, LD; Peng, HK; Reeves, SL; Wing, JJ, 2023)
"Ischemic stroke is characterized by high morbidity, disability, and mortality."1.91Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023)
"A total of 200 children with sickle cell anemia completed neurocognitive testing (109 males, 91 females; mean age 12."1.72Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography. ( Gossett, J; Hankins, JS; Heitzer, AM; Kang, G; King, AA; Krull, K; Longoria, JN; Raches, D; Schreiber, J; Wang, W, 2022)
"Hydroxyurea has been shown to positively modify sickle cell disease pathogenesis, but its use is low among Nigerian sickle cell anaemia (SCA) patients because of effectiveness and safety concerns."1.56Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria. ( Adekola, K; Afolaranmi, TO; Diaku-Akinwumi, IN; Ofakunrin, AOD; Oguche, S; Okpe, ES; Sagay, AS; Zoakah, AI, 2020)
"Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD."1.51Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019)
" These data nicely complement the recently published results from the phase 3 multicenter TCD With Transfusions Changing to Hydroxyurea (TWiTCH) study and suggest that it may be safe to carefully transition a subset of patients from chronic transfusions to hydroxyurea therapy."1.43Hydroxyurea for abnormal TCDs: safe to switch? ( McGann, PT, 2016)
"Hydroxyurea-induced pneumonitis is unusual."1.40[Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014)
"Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis."1.40Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014)
"Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period."1.39Current management of sickle cell anemia. ( McGann, PT; Nero, AC; Ware, RE, 2013)
"Stroke and silent cerebral infarction were not related to clinical hematologic or HbF response to HU."1.39Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013)
"Sickle cell disease is characterized by phenotypic heterogeneity and many genetic modifiers have been identified with elevated Hb F being the most recognized ameliorating factor."1.37Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. ( Adekile, AD, 2011)
"Two patients presenting homozygous hemoglobin S disease died due to septicemia due to non-compliance with antibiotic therapy in one case and severe anemia in one case."1.36Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010)
"Sickle cell disease is the most common inherited disease in the U."1.35The clinical care of adult patients with sickle cell disease. ( Howard, J; Olujohungbe, A, 2008)
"(1) Stroke secondary to PV should be treated with stroke regimen as well as PV therapy, and hydroxycarbamide might have stable benefit and few side effects."1.33[The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke]. ( Ji, XM; Jia, JP; Li, LM; Meng, R; Yang, BF; Zhou, J, 2006)

Research

Studies (134)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.75)18.2507
2000's32 (23.88)29.6817
2010's63 (47.01)24.3611
2020's38 (28.36)2.80

Authors

AuthorsStudies
Hsu, P1
Gay, JC1
Lin, CJ1
Rodeghier, M9
DeBaun, MR23
Cronin, RM2
Abdullahi, SU10
Jibir, BW3
Bello-Manga, H5
Gambo, S7
Inuwa, H2
Tijjani, AG1
Idris, N3
Galadanci, A2
Hikima, MS1
Galadanci, N1
Borodo, A1
Tabari, AM2
Haliru, L4
Suleiman, A2
Ibrahim, J1
Greene, BC2
Ghafuri, DL4
Slaughter, JC1
Kirkham, FJ5
Neville, K4
Kassim, A1
Trevathan, E2
Jordan, LC9
Aliyu, MH7
Farouk, B1
Bahago, GY1
Sani, AM1
Bauman, AA1
King, AA3
Smart, LR2
Ambrose, EE2
Balyorugulu, G1
Songoro, P2
Shabani, I1
Komba, P1
Charles, M2
Howard, TA2
McElhinney, KE1
O'Hara, SM1
Odame, J1
Nakafeero, M2
Adams, J1
Stuber, SE3
Lane, A5
Latham, TS3
Makubi, AN2
Ware, RE21
Longoria, JN1
Wang, W1
Kang, G2
Gossett, J1
Krull, K1
Raches, D1
Schreiber, J1
Heitzer, AM1
Hankins, JS2
Rankine-Mullings, AE1
Nevitt, SJ1
Runge, A1
Brazel, D1
Pakbaz, Z1
Sunusi, S1
Abba, MS2
Sani, S1
Inuwa, HA1
Gambo, A1
Musa, B1
Covert Greene, BV1
Kassim, AA6
Hussaini, N1
Ciobanu, M1
Wuichet, K1
Hodges, B1
Chopra, M1
He, J1
Niu, X1
Wilkerson, K1
Klein, LJ3
Stallings, VA3
Acra, S3
Tang, AY1
Zhou, M1
Maillis, AN1
Lai, KW1
Lane, PA1
Snyder, AB1
Namazzi, R1
Opoka, R1
Conroy, AL1
Datta, D1
Tagoola, A1
Bond, C1
Goings, MJ1
Ryu, MS1
Cusick, SE1
Krebs, NF1
Jang, JH1
Tu, W1
John, CC2
Quinn, CT2
Lane, AC1
Diop, S1
de Montalembert, M3
Reeves, SL1
Peng, HK1
Wing, JJ1
Cogan, LW1
Goel, A1
Anders, D1
Green, NS1
Lisabeth, LD1
Dombkowski, KJ1
Oguro, H1
Takahashi, T1
Wang, K1
Zhou, W1
Jin, X1
Shang, X1
Wu, X1
Wen, L1
Li, S1
Hong, Y1
Ke, J1
Xu, Y1
Yuan, H1
Hu, F1
Karkoska, KA1
Gollamudi, J1
Hyacinth, HI1
Galadanci, AA1
Galadanci, NA5
Ali Abubakar, SA1
Kabo, NA1
Bashir, I1
Galadanci, JA1
Monus, T1
Howell, CM1
Ofakunrin, AOD1
Oguche, S1
Adekola, K1
Okpe, ES1
Afolaranmi, TO1
Diaku-Akinwumi, IN1
Zoakah, AI1
Sagay, AS1
Opoka, RO1
Hume, HA1
Williams, O1
Tymon, J1
Kasirye, P1
Ndugwa, CM1
Hasson, C1
Veling, L1
Rico, J1
Mhaskar, R1
Estcourt, LJ5
Kimber, C1
Hopewell, S5
Trivella, M4
Doree, C2
Abboud, MR4
Schatz, J1
Vichinsky, E1
Fox, CK1
McKinstry, RC2
Telfer, P1
Kraut, MA1
Daraz, L1
Murad, MH1
Nickel, RS1
Margulies, S1
Frazer, B1
Luban, NLC2
Webb, J2
Novelli, EM1
Ali Abubakar, S1
Wudil Jibir, B2
Aminu, H1
Tijjani, A2
Tabari, MA3
Borodo, AM1
Belonwu, R3
Salihu, AS1
Covert C Greene, BV1
Kohli, R1
Wang, WC6
Steinberg, MH4
Lagunju, IA2
Labaeka, A1
Ibeh, JN1
Orimadegun, AE1
Brown, BJ4
Sodeinde, OO3
Allali, S1
Taylor, M1
Brice, J1
Dambatta, AH1
Galadanci, J1
Suleiman, AA1
Gambo, AI1
Khalifa, Y1
Abdulrasheed, S1
Zakari, MA1
Baumann, AA1
Bhattacharya, P1
Sarmah, D1
Dave, KR1
Goswami, A1
Watanabe, M1
Wang, X1
Kalia, K1
Plesnila, N1
Yavagal, DR1
Alvarez, O4
Estepp, JH1
Cong, Z1
Agodoa, I1
Ding, J1
McCarville, MB1
Rankine-Mullings, A1
Reid, M3
Soares, D1
Taylor-Bryan, C1
Wisdom-Phipps, M1
Aldred, K1
Latham, T3
Schultz, WH10
Knight-Madden, J3
Badaloo, A1
Adams, RJ6
Mayer, SL1
Fields, ME3
Hulbert, ML2
Umar Abdullahi, S1
Vance, LD1
Musa Tabari, A1
Ali, S1
Salihu, A2
Amal Galadanci, A1
Shyr, Y2
Phillips, S2
Covert, BV2
Fortin, PM3
Schoenfeld, J1
Tulbert, BH1
Cusack, CA1
McGann, PT3
Williams, TN1
Olupot-Olupot, P1
Tomlinson, GA1
Luís Reis da Fonseca, J1
Kitenge, R1
Mochamah, G1
Wabwire, H1
Stuber, S2
McElhinney, K1
Aygun, B6
Santos, B1
Tshilolo, L2
Lagunju, I2
Oyinlade, AO1
Asinobi, A1
Ibeh, J1
Esione, A1
Barbui, T1
Finazzi, G1
Vannucchi, AM1
De Stefano, V1
Reid, ME1
Casella, JF2
Brambilla, DJ1
Strouse, JJ1
Maier, P1
Dlugash, R1
Avadhani, R1
Vermillion, K1
Tonascia, J1
Voeks, JH1
Hanley, DF1
Thompson, RE1
Lehmann, HP1
Sánchez, LM1
Nieves, RM1
Luden, JR1
Urcuyo, GS1
Berges, ME1
Florencio, C1
Gonzalez, C1
Del Villar, P1
Schultz, W2
Jeste, N1
Mena, R1
Núñez, RM1
Figueroa, CAP1
García-Perdomo, HA1
Guilliams, KP2
Dowling, MM1
Ragan, D1
Binkley, MM1
Mirro, A1
Fellah, S1
Blinder, M1
Eldeniz, C1
Vo, K1
Shimony, JS1
Chen, Y1
An, H1
Lee, JM1
Ford, AL1
Hirtz, D1
Ojewunmi, OO1
Adeyemo, TA1
Ayinde, OC1
Iwalokun, B1
Adekile, A1
Nero, AC1
Sheth, S1
Licursi, M1
Bhatia, M1
Kwiatkowski, JL3
Rigano, P1
Pecoraro, A1
Calvaruso, G1
Iannello, S1
Maggio, A1
Yovetich, NA1
Scott, JP2
Owen, W2
Miller, ST4
Lockhart, A2
Flanagan, J1
Bonner, M1
Mueller, BU2
Dwan, K1
Karanth, SS1
Gupta, A1
Prabhu, M1
Madden, NA1
Jones, GL1
Kalpatthi, R1
Woods, G1
Girard, A1
Ricordel, C1
Poullot, E1
Claeyssen, V1
Decaux, O1
Desrues, B1
Delaval, P1
Jouneau, S1
Helton, KJ2
Kesler, KL1
Driscoll, C1
Heeney, MM3
Jackson, SM1
Krishnamurti, L2
Sarnaik, SA1
Ballas, SK2
Martinez, U1
Savage, M1
Abubakar, S1
Kirkham, F1
Inusa, B1
Sodeinde, O1
Cunningham-Myrie, C1
Abdulkadri, A1
Waugh, A1
Bortolusso Ali, S1
King, LG1
Wood, JC2
Pressel, S2
Rogers, ZR6
Odame, I2
Lee, MT2
Owen, WC1
Cohen, AR3
St Pierre, T1
Davis, BR3
Pressel, SL1
Imran, H2
Luchtman-Jones, L3
Thompson, AA4
Fuh, B2
Chaturvedi, S1
Brown, RC1
Sarnaik, S2
George, A1
Hilliard, L2
Gauger, C2
Piccone, C1
Jackson, S2
Roberts, C1
Kalfa, TA1
Nelson, S1
Nottage, K1
Rhodes, M1
Rothman, JA1
Roberts, D1
Coleman, J1
Bonner, MJ1
Kutlar, A2
Patel, N1
Wood, J1
Piller, L1
Wei, P1
Luden, J1
Mortier, NA4
Bernaudin, F1
Verlhac, S1
Arnaud, C1
Kamdem, A1
Hau, I1
Leveillé, E1
Vasile, M1
Kasbi, F1
Madhi, F1
Fourmaux, C1
Biscardi, S1
Gluckman, E1
Socié, G1
Dalle, JH1
Epaud, R1
Pondarré, C1
Couque, N1
Girard, D1
Ducrocq, R1
Boizeau, P1
Haouari, Z1
Missud, F1
Holvoet, L1
Ithier, G1
Belloy, M1
Odièvre, MH1
Benemou, M1
Benhaim, P1
Retali, B1
Bensaid, P1
Monier, B1
Brousse, V2
Amira, R1
Orzechowski, C1
Lesprit, E1
Mangyanda, L1
Garrec, N1
Elion, J1
Alberti, C1
Baruchel, A1
Benkerrou, M2
Meier, ER2
Rampersad, A1
Ozsahin, H1
Sidani, CA1
Ballourah, W1
El Dassouki, M1
Muwakkit, S1
Dabbous, I1
Dahoui, H1
Al-Kutoubi, A1
Trompeter, S1
Roberts, I1
Olujohungbe, A1
Howard, J1
Suliman, H1
Wali, Y1
Al Saadoon, M1
Zechariah, M1
William, RR1
Gujjar, A1
Pathare, A1
Sandhu, G1
Ranade, A1
Siddiqi, S1
Balderacchi, JL1
Verduzco, LA1
Nathan, DG1
McCarthy, WF1
Castro, O1
Armstrong, FD1
Smith, W1
Ataga, K1
Swerdlow, P1
DeCastro, L1
Waclawiw, MA1
Greenway, A1
Thornburg, CD1
Lê, PQ3
Ferster, A5
Cotton, F1
Vertongen, F1
Vermylen, C3
Vanderfaeillie, A1
Dedeken, L1
Heijmans, C2
Ketelslegers, O1
Dresse, MF3
Gulbis, B3
Coates, TD1
Yovetich, N1
Iyer, RV1
Waclawiw, M1
Helms, RW3
Ali, SB1
Moosang, M1
King, L1
Adekile, AD1
Lebensburger, JD1
Wruck, LM1
Brown, C1
Iyer, R1
Bartolucci, P1
Galactéros, F1
Miller, JL1
McCavit, TL1
Verdure, P1
Lefaucheur, R1
Guegan-Massardier, E1
Triquenot-Bagan, A1
Gerardin, E1
Maltête, D1
Desai, PC1
Deal, AM1
Brittain, JE1
Jones, S1
Hinderliter, A1
Ataga, KI1
Naganuma, M1
Isoda, K1
Nishi, S1
Ito, K1
Hirano, T1
Cherry, MG1
Greenhalgh, J1
Osipenko, L1
Venkatachalam, M1
Boland, A1
Dundar, Y1
Marsh, K1
Dickson, R1
Rees, DC1
Blinder, MA1
Vekeman, F1
Sasane, M1
Trahey, A1
Paley, C1
Duh, MS1
Sumoza, A1
de Bisotti, R1
Sumoza, D1
Fairbanks, V1
Amrolia, PJ1
Almeida, A1
Davies, SC1
Roberts, IA1
Agarwal, MB1
Atweh, GF1
DeSimone, J1
Saunthararajah, Y1
Fathallah, H1
Weinberg, RS1
Nagel, RL1
Fabry, ME1
Buchanan, GR2
Zimmerman, SA3
Sylvestre, PB1
Davis, JS1
Treem, WR1
Haberman, D1
Dufour, D2
Christophe, C1
Kagambega, F1
Corazza, F2
Devalck, C2
Hunninck, K2
Klein, A1
Loop, M1
Maes, P1
Philippet, P2
Sariban, E2
Van Geet, C2
Morales, KH1
Scher, CD1
Styles, L1
Olivieri, N1
Adams, R1
Brambilla, D1
Okpala, IE1
Meng, R1
Zhou, J1
Ji, XM1
Li, LM1
Jia, JP1
Yang, BF1
Shull, EP1
Ahmad, N1
Lee, NJ1
Couillard, S1
Girot, R1
Bader-Meunier, B1
Burgett, S1
Field, JJ1
Lefèvre, N1
Powars, DR1
Schaefer, U1
Micke, O1
Schueller, P1
Willich, N1
Hachulla, E1
Rose, C1
Trillot, N1
Caulier-Leleu, MT1
Pasturel-Michon, U1
Tahriri, P1
Sturbois, G1
Fondu, P1
Feremans, W1
Toppet, M1

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial[NCT00072761]Phase 3196 participants (Actual)Interventional2004-12-31Completed
Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II[NCT02560935]Phase 3440 participants (Actual)Interventional2016-07-19Completed
Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa[NCT02675790]Phase 3120 participants (Anticipated)Interventional2017-01-31Completed
"Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, BRAIN SAFE II"[NCT04750707]Phase 3270 participants (Actual)Interventional2021-03-09Active, not recruiting
REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731]Phase 1/Phase 2635 participants (Actual)Interventional2014-06-30Active, not recruiting
Stroke With Transfusions Changing to Hydroxyurea[NCT00122980]Phase 3134 participants (Actual)Interventional2006-10-31Terminated (stopped due to The study has been stopped due to safety and futility concerns.)
Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life[NCT04705792]40 participants (Anticipated)Interventional2020-01-31Recruiting
TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sic[NCT01425307]Phase 3159 participants (Actual)Interventional2011-08-31Terminated (stopped due to The study was stopped early due to successfully meeting the primary endpoint)
Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization[NCT03111589]102 participants (Actual)Interventional2016-10-31Completed
A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555]Phase 310 participants (Anticipated)Interventional2023-05-01Recruiting
Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159]41 participants (Anticipated)Interventional2012-05-10Active, not recruiting
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082]64 participants (Actual)Interventional2015-09-30Completed
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell[NCT02561312]9 participants (Actual)Observational2015-09-30Completed
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon[NCT04676113]100 participants (Actual)Observational2021-03-01Completed
[NCT00000592]Phase 30 participants Interventional1994-07-31Completed
[NCT00006182]Phase 30 participants Interventional2000-07-31Completed
Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714]160 participants (Anticipated)Interventional2015-12-31Recruiting
Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118]82 participants (Actual)Observational2015-12-31Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion)
Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children[NCT01389024]Phase 228 participants (Actual)Interventional2012-08-16Completed
[NCT00005327]0 participants Observational1993-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct

The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI. (NCT00072761)
Timeframe: From study entry to study exit

Interventioninfarct recurrence per 100 person years (Number)
Transfusion Group2.0
Observation Group4.8

Percentage of Participants With Dose Limiting Toxic Events

An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Hydroxyurea5.1

Barthel Index (Change From Baseline)

The Barthel Index is a measure of activities of daily living (ADL) and assesses the degree of disability in a particular participant. The index records indicators of independence in terms of the disability caused by impairments, such as those that may be sequelae of stroke. The index was used as a record of what the participant did, not as a record of what the participant could do. Barthel scores range from 0 to 100, with higher scores indicating greater independence in daily living activities (caring for oneself). (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)

Interventionunits on a scale (Mean)
Hydroxyurea/Phlebotomy-0.33
Transfusion/Chelation-0.53

Growth and Development - Height (Change From Baseline to Endpoint)

(NCT00122980)
Timeframe: Baseline to end of study participation (up to 136 weeks)

Interventioncm (Mean)
Hydroxyurea/Phlebotomy4.40
Transfusion/Chelation6.61

Growth and Development - Weight (Change From Baseline to Endpoint)

(NCT00122980)
Timeframe: baseline to end of study participation (up to 136 weeks)

Interventionkg (Mean)
Hydroxyurea/Phlebotomy3.83
Transfusion/Chelation6.36

Liver Iron Content (LIC) Change-from-baseline

LIC change-from-baseline is the second component of the composite primary endpoint. LIC was measured by quantitative liver biopsy at baseline and at 30 months or exit from the study.LIC values were transformed into Log10 values prior to computing the change from baseline. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)

Interventionmg ferritin/gram dry weight liver (Log Mean)
Hydroxyurea/Phlebotomy-0.006
Transfusion/Chelation-0.120

Woodcock-Johnson Test of Cognitive Abilities (WJ-C) and Achievement (WJ-III) (Change From Baseline)- Verbal Ability

This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Higher scores mean better abilities/achievements. Scaled scores range from 0-100. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)

Interventionunits on a scale (Mean)
Hydroxyurea/Phlebotomy1.829
Transfusion/Chelation-2.487

Occurrence of an Adjudicated Secondary Stroke During the 30-month Treatment Period

Secondary stroke is the first component of the composite primary endpoint and considers the number of participants with recurrent secondary stroke events during 30 months of treatment. Stroke was defined as any clinical event with brain injury due to vascular disease. All neurological events underwent formal stroke adjudication. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)

,
Interventionparticipants (Number)
StrokeNo Stroke
Hydroxyurea/Phlebotomy760
Transfusion/Chelation066

Pediatric Quality of Life (PedsQL) - Child Report (Change From Baseline)

The PedsQLTM Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, midpoint (week 64), and study exit (up to 30 months of treatment)

,
Interventionunits on a scale (Mean)
Midpoint: Emotional Functioning Score (n=47, 57)Exit: Emotional Functioning Score (n=55, 54)Midpoint: Physical Functioning Score (n=47, 57)Exit: Physical Functioning Score (n=55, 54)Midpoint: School Functioning Score (n=47, 57)Exit: School Functioning Score (n=55, 53)Midpoint: Social Functioning Score (n=46, 57)Exit: Social Functioning Score (n=54, 54)Midpoint: Total Functioning Score (n=47, 57)Exit: Total Functioning Score (n=55, 54)Midpoint: Psychosocial Health Summary (n=47, 57)Exit: Psychosocial Health Summary Score (n=57, 54)
Hydroxyurea/Phlebotomy1.063.820.463.41-1.031.762.393.130.352.900.282.65
Transfusion/Chelation3.513.803.182.034.562.741.842.873.262.623.302.93

Pediatric Quality of Life (PedsQL) - Parent Report (Change From Baseline)

The PedsQL(TM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, mid-point (week 64), and study exit after up to 30-month treatment period (due to study termination)

,
Interventionunits on a scale (Mean)
Mid-point: Emotional Functioning Score (n=43,54)Exit: Emotional Functioning Score (n=52, 54)Mid-point: Physical Functioning Score (n=43,64)Exit: Physical Functioning Score (n=53, 54)Mid-point: School Functioning (n=43, 54)Exit: School Functioning (n=51,53)Mid-point : Social Functioning Score (n=42, 54)Exit : Social Functioning Score (n=53, 54)Mid-point: Total Functioning Score (n=43, 54)Exit: Total Functioning Score (n=53, 54)Mid-point: Psychosocial Health Summary (n=43,54)Exit: Psychosocial Health Summary (n=53, 54)
Hydroxyurea/Phlebotomy-0.99-1.25-1.712.273.14-0.293.692.670.391.131.610.33
Transfusion/Chelation5.565.65-0.57-0.98-3.342.83-0.35-1.110.201.090.592.11

Woodcock-Johnson Test of Cognitive Abilities (WJ-C) and Achievement (WJ-III) (Change From Baseline)-Excluding Verbal

This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Scaled scores range from 0-100. Higher scores mean better abilities/achievements. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)

,
Interventionunits on a scale (Mean)
General intellectual ability (n=33, 35)Processing speed (n=35, 33)Working memory (n=33, 34)Broad attention (n=31, 33)Executive processes (n=32, 33)Broad reading (n=34, 33)Broad math (n=34, 33)
Hydroxyurea/Phlebotomy-1.64-0.80-7.67-4.36-0.72-0.29-3.53
Transfusion/Chelation-3.002.06-2.65-0.49-1.15-0.94-5.76

Change of Baseline in Hepatic Iron Overload as Assessed by Liver Iron Concentration

This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months

Interventionmg FE per g dry weight liver (Mean)
Standard Therapy2.4
Treatment Arm-1.9

Change of Baseline in Hepatic Iron Overload as Assessed by Serum Ferritin

This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months

Interventionng per mL (Mean)
Standard Therapy-38
Treatment Arm-1805

Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side

The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period. (NCT01425307)
Timeframe: Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).

Interventioncm/sec (Mean)
Treatment Arm138
Standard Therapy143

Number of Participants Randomized

We will evaluate the number of participants consented and fully screened that were randomized to hydroxyurea or placebo. (NCT01389024)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Participants Completing Screening Procedures12

Number of Randomized Participants With Central Nervous System Complications

A composite of abnormally elevated cerebral blood flow velocity as measured by transcranial Doppler ultrasound, silent cerebral infarct, or stroke. (NCT01389024)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Hydroxyurea1
Placebo4

Severe Adverse Events (SAE) Attributed to Sedated MRIs

Number of sedated MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years

InterventionMRIs (Count of Units)
MRIs With Sedation.3

Severe Adverse Events (SAE) Attributed to Study Procedures

Number of MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years

InterventionMRIs (Count of Units)
Participants Undergoing MRIs3

Reviews

44 reviews available for hydroxyurea and Apoplexy

ArticleYear
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    The Cochrane database of systematic reviews, 2022, 09-01, Volume: 9

    Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Hemoglobin, Sickle; Hu

2022
Stroke in sickle cell disease and the promise of recent disease modifying agents.
    Journal of the neurological sciences, 2022, 11-15, Volume: 442

    Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Hydroxyurea; Strok

2022
Molecular and environmental contributors to neurological complications in sickle cell disease.
    Experimental biology and medicine (Maywood, N.J.), 2023, Volume: 248, Issue:15

    Topics: Anemia, Sickle Cell; Blood Transfusion; Cognitive Dysfunction; Humans; Hydroxyurea; Stroke

2023
Current and emerging treatments for sickle cell disease.
    JAAPA : official journal of the American Academy of Physician Assistants, 2019, Volume: 32, Issue:9

    Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents;

2019
The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
    Medicine, 2019, Volume: 98, Issue:51

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Humans; Hydroxyurea; Stroke

2019
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2020, 04-06, Volume: 4

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni

2020
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2020, 07-27, Volume: 7

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea

2020
Fetal hemoglobin in sickle cell anemia.
    Blood, 2020, 11-19, Volume: 136, Issue:21

    Topics: Anemia, Sickle Cell; beta-Globins; Fetal Hemoglobin; gamma-Globins; Gene Editing; Gene Expression Re

2020
Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.
    Journal of the neurological sciences, 2021, 08-15, Volume: 427

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Developing Countries; Humans; Hydroxyurea; Stroke;

2021
Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
    NeoReviews, 2021, Volume: 22, Issue:8

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cognition; Humans; Hy

2021
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2017, 05-13, Volume: 5

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni

2017
Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    The Cochrane database of systematic reviews, 2018, 08-01, Volume: 8

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Erythrocyte Transfusion; Humans; Hydrox

2018
Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
    Journal of child health care : for professionals working with children in the hospital and community, 2020, Volume: 24, Issue:1

    Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke

2020
Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.
    Stroke, 2019, Volume: 50, Issue:2

    Topics: Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Arteries; Cerebrovas

2019
Sickle Cell Disease and Stroke.
    Pediatric neurology, 2019, Volume: 95

    Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Humans; Hydroxyurea; Stroke; Ul

2019
Current perspectives of sickle cell disease in Nigeria: changing the narratives.
    Expert review of hematology, 2019, Volume: 12, Issue:8

    Topics: Anemia, Sickle Cell; Genetic Counseling; Hematopoietic Stem Cell Transplantation; Hemoglobins; Human

2019
Sickle cell disease: time for a closer look at treatment options?
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Africa; Anemia, Sickle Cell; Brain Damage, Chronic; Cardiovascular Diseases; Chelation Therapy; Chro

2013
Stroke in patients with sickle cell disease.
    Expert review of hematology, 2013, Volume: 6, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Vessels; Brain; Cerebral Infarction; Humans; Hydroxy

2013
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2013, Nov-14, Issue:11

    Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Early Termination of Clinical Trials; Humans; Hydroxy

2013
The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chest Pain; Child; Hematopoietic Stem C

2014
Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    American journal of hematology, 2016, Volume: 91, Issue:1

    Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antisickling Agents; Bloo

2016
Pediatric sickle cell disease: past successes and future challenges.
    Pediatric research, 2017, Volume: 81, Issue:1-2

    Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, Pre

2017
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2017, 01-17, Volume: 1

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea

2017
Sickle cell disease.
    Lancet (London, England), 2017, 07-15, Volume: 390, Issue:10091

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise

2017
Sickle cell disease.
    Lancet (London, England), 2017, 07-15, Volume: 390, Issue:10091

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise

2017
Sickle cell disease.
    Lancet (London, England), 2017, 07-15, Volume: 390, Issue:10091

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise

2017
Sickle cell disease.
    Lancet (London, England), 2017, 07-15, Volume: 390, Issue:10091

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise

2017
MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
    Pediatric blood & cancer, 2008, Volume: 51, Issue:5

    Topics: Anemia, Sickle Cell; Antisickling Agents; Brain; Clinical Trials as Topic; Humans; Hydroxyurea; Infa

2008
Haemoglobin F modulation in childhood sickle cell disease.
    British journal of haematology, 2009, Volume: 144, Issue:3

    Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Child; Clinical Trials as T

2009
Sickle cell disease and stroke.
    Blood, 2009, Dec-10, Volume: 114, Issue:25

    Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents; Antisickling Agents; Blood Transfusion; Bone Marrow T

2009
What is the evidence for using hydroxyurea for secondary stroke prevention?
    Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011

    Topics: Blood Transfusion; Child; Humans; Hydroxyurea; Male; Secondary Prevention; Stroke

2011
Prospects for primary stroke prevention in children with sickle cell anaemia.
    British journal of haematology, 2012, Volume: 157, Issue:1

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Transfusion; Brain

2012
Clinical management of adult sickle-cell disease.
    Current opinion in hematology, 2012, Volume: 19, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Kidney Disea

2012
Sickle cell disease in children.
    Drugs, 2012, May-07, Volume: 72, Issue:7

    Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Genetic Predisposition to Disease;

2012
Sickle cell disease.
    Pediatrics in review, 2012, Volume: 33, Issue:5

    Topics: Acute Pain; Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Erythrocyte Trans

2012
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:43

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Cerebrovas

2012
Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
    British journal of haematology, 2003, Volume: 120, Issue:5

    Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Central Nervous System Diseas

2003
Advances in management of sickle cell disease.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:8

    Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Tra

2003
Hemoglobinopathies.
    Hematology. American Society of Hematology. Education Program, 2003

    Topics: Animals; Azacitidine; Butyrates; Cerebral Hemorrhage; Decitabine; Disease Models, Animal; DNA Methyl

2003
Predicting clinical severity in sickle cell anaemia.
    British journal of haematology, 2005, Volume: 129, Issue:4

    Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Genetic Predi

2005
New therapies for sickle cell disease.
    Hematology/oncology clinics of North America, 2005, Volume: 19, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Huma

2005
The pathophysiology, prevention, and treatment of stroke in sickle cell disease.
    Current opinion in hematology, 2007, Volume: 14, Issue:3

    Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Stroke; Ultrasonography, Doppler, Trans

2007
Hematopoietic cell transplantation: a curative option for sickle cell disease.
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:8

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Hemato

2007
Management of cerebral vasculopathy in children with sickle cell anaemia.
    British journal of haematology, 2000, Volume: 108, Issue:4

    Topics: Adolescent; Adult; Algorithms; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation;

2000
[What vascular events suggest a myeloproliferative disorder?].
    Journal des maladies vasculaires, 2000, Volume: 25, Issue:5

    Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi

2000
Stroke prevention and treatment in sickle cell disease.
    Archives of neurology, 2001, Volume: 58, Issue:4

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Humans; Hy

2001
Acute complications of sickle cell disease in children.
    Drug and therapeutics bulletin, 2001, Volume: 39, Issue:5

    Topics: Abdominal Pain; Acute Disease; Adolescent; Analgesics; Anemia, Aplastic; Anemia, Sickle Cell; Animal

2001

Trials

33 trials available for hydroxyurea and Apoplexy

ArticleYear
Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial.
    Blood advances, 2021, 12-14, Volume: 5, Issue:23

    Topics: Blood Transfusion; Cerebral Infarction; Child; Cost-Benefit Analysis; Humans; Hydroxyurea; Stroke; U

2021
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    The Lancet. Haematology, 2022, Volume: 9, Issue:1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Method; Female; Humans; Hyd

2022
Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
    BMC research notes, 2022, Jan-04, Volume: 15, Issue:1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Nigeria; Stroke; Ultrasonography, Dop

2022
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
    Acta haematologica, 2023, Volume: 146, Issue:2

    Topics: Adolescent; Africa South of the Sahara; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans

2023
PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
    Transactions of the American Clinical and Climatological Association, 2022, Volume: 132

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Stroke

2022
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
    Blood, 2023, 02-23, Volume: 141, Issue:8

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention;

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Blood advances, 2023, 06-13, Volume: 7, Issue:11

    Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea

2023
Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial.
    Blood advances, 2023, Jul-11, Volume: 7, Issue:13

    Topics: Adolescent; Adult; Africa; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Stroke; Zinc

2023
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    The Lancet. Haematology, 2023, Volume: 10, Issue:4

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Stroke; Tanzania

2023
Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
    Blood, 2020, 06-18, Volume: 135, Issue:25

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Donors; Blood Safety; Blood Transfusion; Chelation The

2020
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
    American journal of hematology, 2020, Volume: 95, Issue:9

    Topics: Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Nigeria; Stroke

2020
Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
    Journal of pediatric hematology/oncology, 2022, 01-01, Volume: 44, Issue:1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male

2022
What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
    British journal of haematology, 2021, Volume: 194, Issue:2

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Child; Child, Preschool; Female; Hemo

2021
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
    British journal of haematology, 2021, Volume: 195, Issue:4

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati

2021
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
    American journal of hematology, 2017, Volume: 92, Issue:8

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hospit

2017
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
    American journal of hematology, 2018, Volume: 93, Issue:4

    Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child,

2018
Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
    Blood advances, 2018, 11-30, Volume: 2, Issue:Suppl 1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Capacity Building; Child; Dominican Republic; Humans; Hydr

2018
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.
    Blood, 2019, 05-30, Volume: 133, Issue:22

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Cerebrovascular Circulation; Child; Female; Humans; Hydroxyu

2019
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Pediatric neurology, 2019, Volume: 95

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu

2019
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Pediatric neurology, 2019, Volume: 95

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu

2019
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Pediatric neurology, 2019, Volume: 95

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu

2019
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Pediatric neurology, 2019, Volume: 95

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu

2019
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelat

2013
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
    Blood, 2014, Aug-07, Volume: 124, Issue:6

    Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Brain; Cerebrovascular Circ

2014
Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Feasibility Studies; Female; Foll

2015
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    American journal of hematology, 2015, Volume: 90, Issue:9

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre

2015
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    British journal of haematology, 2016, Volume: 172, Issue:1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Ferritins; Humans; Hydroxyurea; Iron; Iron

2016
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Lancet (London, England), 2016, Feb-13, Volume: 387, Issue:10019

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Cerebr

2016
Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.
    Blood, 2016, Apr-07, Volume: 127, Issue:14

    Topics: Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Cerebrovascular Circulation; Female; Fo

2016
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
    American journal of hematology, 2010, Volume: 85, Issue:6

    Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical

2010
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
    Pediatric blood & cancer, 2011, Dec-01, Volume: 57, Issue:6

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Child, Preschool; Erythrocyte Tran

2011
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
    American journal of hematology, 2012, Volume: 87, Issue:4

    Topics: Anemia, Sickle Cell; Autoantibodies; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child,

2012
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi

2012
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi

2012
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi

2012
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi

2012
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    The Journal of pediatrics, 2005, Volume: 147, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C

2005
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    The Journal of pediatrics, 2005, Volume: 147, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C

2005
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    The Journal of pediatrics, 2005, Volume: 147, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C

2005
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    The Journal of pediatrics, 2005, Volume: 147, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C

2005
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
    Blood, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres

2007
Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial.
    Hematology. American Society of Hematology. Education Program, 2007

    Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Multicenter Studies as Topic; Randomized Controlled Trials

2007

Other Studies

57 other studies available for hydroxyurea and Apoplexy

ArticleYear
Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:11

    Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Child; Female; Humans; Hydr

2022
Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy.
    Blood advances, 2023, 08-08, Volume: 7, Issue:15

    Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Midd

2023
Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies

2023
Hydroxyurea: how much is enough?
    Blood, 2023, 02-23, Volume: 141, Issue:8

    Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention; Stroke

2023
Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa.
    The Lancet. Haematology, 2023, Volume: 10, Issue:4

    Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Stroke

2023
Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines.
    JAMA network open, 2023, 03-01, Volume: 6, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Cross-Sectional Studies; Humans; Hydroxyurea; Male; Medicaid; Strok

2023
[A case of recurrent non embolic stroke with non-fluent aphasia due to polycythemia vera].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2023, Volume: 60, Issue:2

    Topics: Aged; Aphasia; Cerebral Infarction; Female; Humans; Hydroxyurea; Polycythemia Vera; Stroke

2023
Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke.
    Nanoscale, 2023, Jul-13, Volume: 15, Issue:27

    Topics: Animals; Blood-Brain Barrier; Brain; Brain Ischemia; Endothelial Cells; Hydroxyurea; Hypoxia; Ischem

2023
Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    American journal of hematology, 2019, Volume: 94, Issue:11

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infa

2019
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Journal of tropical pediatrics, 2020, 06-01, Volume: 66, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hematocrit; H

2020
Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.
    Haematologica, 2020, Volume: 105, Issue:6

    Topics: Anemia, Sickle Cell; Blood Flow Velocity; Humans; Hydroxyurea; Stroke; Uganda; Ultrasonography, Dopp

2020
Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
    Blood, 2020, 05-28, Volume: 135, Issue:22

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Donors; Blood Safety; Blood Transfusion; Child; Chil

2020
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
    Blood advances, 2020, 04-28, Volume: 4, Issue:8

    Topics: Adult; Anemia, Sickle Cell; Child; Hematology; Hemoglobin, Sickle; Humans; Hydroxyurea; Stroke; Unit

2020
COVID-19 and SCA: an old friend comes to the rescue.
    Blood, 2020, 05-28, Volume: 135, Issue:22

    Topics: Betacoronavirus; Child; Coronavirus Infections; COVID-19; Friends; Humans; Hydroxyurea; Pandemics; P

2020
Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:4

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro

2021
Chronic organ injuries in children with sickle cell disease.
    Haematologica, 2021, 06-01, Volume: 106, Issue:6

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke

2021
Transverse melanonychia and palmar hyperpigmentation secondary to hydroxyurea therapy.
    Cutis, 2017, Volume: 99, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; Female; Hand; Humans; Hydroxyurea

2017
Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati

2019
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.
    Blood cancer journal, 2018, 11-07, Volume: 8, Issue:11

    Topics: Humans; Hydroxyurea; Leukocyte Count; Myeloid Cells; Myeloproliferative Disorders; Recurrence; Strok

2018
Hydroxyurea for Primary Stroke Prevention: The time draweth nigh.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Nigeria; Stroke

2019
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease.
    Clinical trials (London, England), 2019, Volume: 16, Issue:1

    Topics: Anemia, Sickle Cell; Child; Clinical Trials as Topic; Cognitive Dysfunction; Endpoint Determination;

2019
Current management of sickle cell anemia.
    Cold Spring Harbor perspectives in medicine, 2013, Aug-01, Volume: 3, Issue:8

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Early Diagnosis; Evidence

2013
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr

2013
Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
    The Nigerian postgraduate medical journal, 2013, Volume: 20, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Disabled Children; Female; Humans

2013
Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
    Singapore medical journal, 2014, Volume: 55, Issue:1

    Topics: Female; Humans; Hydroxyurea; Hyperpigmentation; Middle Aged; Nail Diseases; Nails; Stroke; Thrombocy

2014
Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:6

    Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool;

2014
[Hydroxyurea-induced pneumonia].
    Revue des maladies respiratoires, 2014, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Lymphoproliferative Disorders; Pneumonia;

2014
Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
    Hemoglobin, 2014, Volume: 38, Issue:5

    Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Ischemia; Echocardiography, Transesophageal;

2014
Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:9

    Topics: Adolescent; Anemia, Sickle Cell; Blood Cell Count; Blood Flow Velocity; Blood Transfusion; Cerebral

2015
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:10

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cost-Benefit Analysis; Developing Countries; Female

2015
Hydroxyurea for abnormal TCDs: safe to switch?
    Blood, 2016, Apr-07, Volume: 127, Issue:14

    Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Female; Humans; Hydroxyurea; Ma

2016
Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.
    British journal of haematology, 2016, Volume: 173, Issue:6

    Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Female; Follow-U

2016
Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis.
    American journal of hematology, 2008, Volume: 83, Issue:10

    Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Dura Mater; Follow-Up Studies; He

2008
The clinical care of adult patients with sickle cell disease.
    British journal of hospital medicine (London, England : 2005), 2008, Volume: 69, Issue:11

    Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Genetic Testing; Heart Diseases; Humans; Hy

2008
Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:1

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Ci

2009
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia,

2009
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    American journal of hematology, 2011, Volume: 86, Issue:4

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Combined Modalit

2011
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
    Medecine tropicale : revue du Corps de sante colonial, 2010, Volume: 70, Issue:5-6

    Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation;

2010
Is it time to SWiTCH to composite primary endpoints?
    Pediatric blood & cancer, 2011, Dec-01, Volume: 57, Issue:6

    Topics: Anemia, Sickle Cell; Erythrocyte Transfusion; Humans; Hydroxyurea; Iron Overload; Stroke

2011
Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.
    American journal of hematology, 2011, Volume: 86, Issue:10

    Topics: Anemia, Sickle Cell; Child; Cohort Studies; Female; Humans; Hydroxyurea; Male; Recurrence; Stroke

2011
Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
    Hemoglobin, 2011, Volume: 35, Issue:5-6

    Topics: alpha-Thalassemia; Anemia, Sickle Cell; Arabs; Femur Head Necrosis; Fetal Hemoglobin; Genetic Associ

2011
Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation.
    Revue neurologique, 2012, Volume: 168, Issue:6-7

    Topics: Adult; Anticoagulants; Antineoplastic Agents; Brain Ischemia; Diplopia; Female; Humans; Hydroxyurea;

2012
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.
    American journal of hematology, 2012, Volume: 87, Issue:10

    Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Bilirubin; Blood Pressure; Body Mass

2012
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:1

    Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic

2014
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:5

    Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Blood Transfusion; Chelation Therapy; Child; Ch

2013
Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    American journal of hematology, 2002, Volume: 71, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal Hemoglo

2002
Expanding the role of hydroxyurea in children with sickle cell disease.
    The Journal of pediatrics, 2004, Volume: 145, Issue:3

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Stroke; Transfusion Reaction;

2004
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    The Journal of pediatrics, 2004, Volume: 145, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro

2004
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
    Blood, 2005, Apr-01, Volume: 105, Issue:7

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Belgium; Child; Child, Preschool; Femal

2005
Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
    The Journal of pediatrics, 2005, Volume: 147, Issue:4

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Secondary Preventio

2005
[The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke].
    Zhonghua nei ke za zhi, 2006, Volume: 45, Issue:5

    Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Harringtonines; Hemato

2006
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion

2007
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion

2007
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion

2007
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion

2007
Steroid treatment in children with sickle-cell disease.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr

2007
Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
    Blood, 2008, Jan-15, Volume: 111, Issue:2

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres

2008
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
    Blood, 1999, Nov-01, Volume: 94, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion

1999
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
    Radiology, 2000, Volume: 216, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
    Blood, 2001, Jun-01, Volume: 97, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Antisickling Agents; Arteri

2001